Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
25 janv. 2024 16h05 HE
|
Travere Therapeutics, Inc.
Travere Therapeutics has entered into an exclusive licensing agreement with Renalys Pharma to bring sparsentan to patients in Japan.
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
13 oct. 2023 16h30 HE
|
Travere Therapeutics, Inc.
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for...
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
21 sept. 2023 07h30 HE
|
Travere Therapeutics, Inc.
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and eGFR chronic slope (1.1 mL/min/1.73m2 per year)...
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
01 avr. 2023 04h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing...
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
15 nov. 2022 08h00 HE
|
Travere Therapeutics, Inc.
Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease. SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE)...
Travere Therapeutics Reports Third Quarter 2022 Financial Results
27 oct. 2022 16h01 HE
|
Travere Therapeutics, Inc.
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for...
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
26 oct. 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present data from its sparsentan programs,...
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
16 mai 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New...
Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021
02 nov. 2021 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data...
Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis
07 sept. 2021 08h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug...